{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:02:06Z","timestamp":1753894926325,"version":"3.41.2"},"reference-count":35,"publisher":"Becaris Publishing Limited","funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>This online interactive survey investigated lipid-lowering approaches of French cardiologists in high- and very high-cardiovascular risk patients with hypercholesterolemia.<jats:bold>Materials &amp; methods:<\/jats:bold>Physicians assessed three hypothetical patients at three clinic visits, and selected the patients\u2019\u00a0cardiovascular risk category, target low-density lipoprotein cholesterol (LDL-C)\u00a0and treatment.<jats:bold>Results:<\/jats:bold>A total of\u00a0162 physicians completed 480 risk assessments; 58% of assessments correctly categorized the hypothetical patients. Most physicians chose the correct LDL-C target for one of the very high-risk patients, but higher-than-recommended targets were selected for the other very high-risk patient and the high-risk patient. Statins were the most commonly chosen treatment.<jats:bold>Conclusion:<\/jats:bold>French cardiologists often underestimate cardiovascular risk in patients with hypercholesterolemia, select a higher-than-recommended LDL-C target and prescribe less intensive treatment than that recommended by guidelines.<\/jats:p>","DOI":"10.57264\/cer-2022-0181","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:43:54Z","timestamp":1678358634000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study"],"prefix":"10.57264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-1297","authenticated-orcid":false,"given":"Jean","family":"Ferri\u00e8res","sequence":"first","affiliation":[{"name":"Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France"},{"name":"INSERM UMR 1295, Toulouse Paul Sabatier University, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-9629","authenticated-orcid":false,"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Metabolism &amp; Cardiovascular Prevention, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, E3M Institute &amp; IHU Cardiometabolic (ICAN), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-7978","authenticated-orcid":false,"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[{"name":"Team PEC2, EA 7460, University of Bourgogne Franche-Comt\u00e9, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-9511","authenticated-orcid":false,"given":"Michel","family":"Krempf","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bret\u00e9ch\u00e9 Clinic, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-8311","authenticated-orcid":false,"given":"Jean-Jacques","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Franco-Britannique, Levallois, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Roux","sequence":"additional","affiliation":[{"name":"Clinical Research Department, FAST4, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-6551","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Schiele","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHU Besan\u00e7on, University of Franche-Comt\u00e9, Besan\u00e7on, EA 3920, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"40","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe\u2013epidemiological update 2015","volume":"36","author":"Townsend N","year":"2015","unstructured":"Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe\u2013epidemiological update 2015. Eur. Heart J. 36(40), 2696\u20132705 (2015).","journal-title":"Eur. Heart J."},{"issue":"1","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","article-title":"European Society of Cardiology: cardiovascular disease statistics 2019","volume":"41","author":"Timmis A","year":"2020","unstructured":"Timmis A, Townsend N, Gale CP European Society of Cardiology: cardiovascular disease statistics 2019. Eur. Heart J. 41(1), 12\u201385 (2020).","journal-title":"Eur. Heart J."},{"issue":"6","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.acvd.2016.01.011","article-title":"Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database","volume":"109","author":"Tuppin P","year":"2016","unstructured":"Tuppin P, Rivi\u00e8re S, Rigault A Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Arch. Cardiovasc. Dis. 109(6\u20137), 399\u2013411 (2016).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"32","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society consensus panel","volume":"38","author":"Ference BA","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society consensus panel. Eur. Heart J. 38(32), 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"issue":"13","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski MJ","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO Time course of LDL cholesterol exposure and cardiovascular disease event risk. J. Am. Coll. Cardiol. 76(13), 1507\u20131516 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.acvd.2021.12.004","article-title":"Impact of lowering low-density lipoprotein cholesterol thresholds on the proportion of adults requiring an intervention: application of the 2019 ESC\/EAS guidelines for the management of dyslipidaemia to the French population","volume":"115","author":"Olie V","year":"2022","unstructured":"Olie V, Grave C, Gabet A. Impact of lowering low-density lipoprotein cholesterol thresholds on the proportion of adults requiring an intervention: application of the 2019 ESC\/EAS guidelines for the management of dyslipidaemia to the French population. Arch. Cardiovasc. Dis. 115(2), 106\u2013108 (2022).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"50","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"e23445","DOI":"10.1097\/MD.0000000000023445","article-title":"Prevalence and management of hypercholesterolemia in France, the Esteban observational study","volume":"99","author":"Blacher J","year":"2020","unstructured":"Blacher J, Gabet A, Vallee A Prevalence and management of hypercholesterolemia in France, the Esteban observational study. Medicine (Baltimore) 99(50), e23445 (2020).","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry","volume":"277","author":"Beliard S","year":"2018","unstructured":"Beliard S, Boccara F, Cariou B High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry. Atherosclerosis 277, 334\u2013340 (2018).","journal-title":"Atherosclerosis"},{"issue":"6","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cjca.2019.02.013","article-title":"Prevalence and treatment of familial hypercholesterolemia in France","volume":"35","author":"Berard E","year":"2019","unstructured":"Berard E, Bongard V, Haas B Prevalence and treatment of familial hypercholesterolemia in France. Can. J. Cardiol. 35(6), 744\u2013752 (2019).","journal-title":"Can. J. Cardiol."},{"issue":"8","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"e0255345","DOI":"10.1371\/journal.pone.0255345","article-title":"Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: a retrospective longitudinal cohort study","volume":"16","author":"Ferrieres J","year":"2021","unstructured":"Ferrieres J, Banks V, Pillas D Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: a retrospective longitudinal cohort study. PLoS ONE 16(8), e0255345 (2021).","journal-title":"PLoS ONE"},{"issue":"3","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.acvd.2016.11.004","article-title":"Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS\/CHD study","volume":"110","author":"Ferrieres J","year":"2017","unstructured":"Ferrieres J, Rouyer MV, Lautsch D Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS\/CHD study. Arch. Cardiovasc. Dis. 110(3), 167\u2013178 (2017).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"5","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"e0250676","DOI":"10.1371\/journal.pone.0250676","article-title":"Diagnosis, risk factors and management of diabetes mellitus in HIV-infected persons in France: a real-life setting study","volume":"16","author":"Kousignian I","year":"2021","unstructured":"Kousignian I, Sautereau A, Vigouroux C Diagnosis, risk factors and management of diabetes mellitus in HIV-infected persons in France: a real-life setting study. PLoS ONE 16(5), e0250676 (2021).","journal-title":"PLoS ONE"},{"issue":"8","key":"e_1_3_8_16_2","first-page":"690","article-title":"Nonadherence, clinical inertia, or therapeutic inertia?","volume":"15","author":"Allen JD","year":"2009","unstructured":"Allen JD, Curtiss FR, Fairman KA. Nonadherence, clinical inertia, or therapeutic inertia? J. Manag. Care Pharm. 15(8), 690\u2013695 (2009).","journal-title":"J. Manag. Care Pharm."},{"issue":"10","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1185\/03007995.2014.941979","article-title":"Reaching low density lipoprotein cholesterol targets","volume":"30","author":"Rizos CV","year":"2014","unstructured":"Rizos CV, Barkas F, Elisaf MS. Reaching low density lipoprotein cholesterol targets. Curr. Med. Res. Opin. 30(10), 1967\u20131969 (2014).","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7326\/0003-4819-141-10-200411160-00008","article-title":"Measuring the quality of physician practice by using clinical vignettes: a prospective validation study","volume":"141","author":"Peabody JW","year":"2004","unstructured":"Peabody JW, Luck J, Glassman P Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann. Intern. Med. 141(10), 771\u2013780 (2004).","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.acvd.2011.04.007","article-title":"Assessment of cardiovascular risk in primary care patients in France","volume":"104","author":"Bruckert E","year":"2011","unstructured":"Bruckert E, Bonnelye G, Thomas-Delecourt F, Andr\u00e9 L, Delaage PH. Assessment of cardiovascular risk in primary care patients in France. Arch. Cardiovasc. Dis. 104(6\u20137), 381\u2013387 (2011).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"2","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"e017711","DOI":"10.1136\/bmjopen-2017-017711","article-title":"Can doctors and patients correctly estimate cardiovascular risk? A cross-sectional study in primary care","volume":"8","author":"Liew SM","year":"2018","unstructured":"Liew SM, Lee WK, Khoo EM Can doctors and patients correctly estimate cardiovascular risk? A cross-sectional study in primary care. BMJ Open 8(2), e017711 (2018).","journal-title":"BMJ Open"},{"issue":"10","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/qjmed\/hcq122","article-title":"Barriers to cardiovascular disease risk scoring and primary prevention in Europe","volume":"103","author":"Hobbs FD","year":"2010","unstructured":"Hobbs FD, Jukema JW, Da Silva PM, Mccormack T, Catapano AL. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 103(10), 727\u2013739 (2010).","journal-title":"QJM"},{"issue":"5","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.hjr.0000219112.02544.24","article-title":"Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology","volume":"13","author":"Graham IM","year":"2006","unstructured":"Graham IM, Stewart M, Hertog MG. Cardiovascular Round Table Task Force. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur. J. Cardiovasc. Prev. Rehabil. 13(5), 839\u2013845 (2006).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"15","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir K","year":"2015","unstructured":"Nasir K, Bittencourt MS, Blaha MJ Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 66(15), 1657\u20131668 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.105.580696","article-title":"Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"113","author":"Mcclelland RL","year":"2006","unstructured":"Mcclelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 113(1), 30\u201337 (2006).","journal-title":"Circulation"},{"issue":"25","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell JD","year":"2018","unstructured":"Mitchell JD, Fergestrom N, Gage BF Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J. Am. Coll. Cardiol. 72(25), 3233\u20133242 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"34","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren FLJ","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42(34), 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society task force","volume":"325","author":"Averna M","year":"2021","unstructured":"Averna M, Banach M, Bruckert E Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society task force. Atherosclerosis 325, 99\u2013109 (2021).","journal-title":"Atherosclerosis"},{"issue":"8","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ijcp.12419","article-title":"Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. a case-control study","volume":"68","author":"Diaz Rodriguez A","year":"2014","unstructured":"Diaz Rodriguez A, Murga N, Camafort-Babkowski M Therapeutic inertia in hypercholesterolaemia is associated with ischaemic events in primary care patients. a case-control study. Int. J. Clin. Pract. 68(8), 1001\u20131009 (2014).","journal-title":"Int. J. Clin. Pract."},{"issue":"24","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/jcm10245938","article-title":"Control of low-density lipoprotein cholesterol in secondary prevention of coronary artery disease in real-life practice: the DAUSSET study in French cardiologists","volume":"10","author":"Ferrieres J","year":"2021","unstructured":"Ferrieres J, Roubille F, Farnier M Control of low-density lipoprotein cholesterol in secondary prevention of coronary artery disease in real-life practice: the DAUSSET study in French cardiologists. J. Clin. Med. 10(24), 5938 (2021).","journal-title":"J. Clin. Med."},{"issue":"7","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/eci.13528","article-title":"Management of LDL-cholesterol levels in patients with diabetes mellitus in cardiology practice: real-life evidence of under-treatment from the EPHESUS registry","volume":"51","author":"Mert KU","year":"2021","unstructured":"Mert KU, Basaran O, Mert GO Management of LDL-cholesterol levels in patients with diabetes mellitus in cardiology practice: real-life evidence of under-treatment from the EPHESUS registry. Eur. J. Clin. Invest. 51(7), e13528 (2021).","journal-title":"Eur. J. Clin. Invest."},{"issue":"11","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray KK","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol. 28(11), 1279\u20131289 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.clinthera.2018.07.008","article-title":"Lipid-lowering therapy and goal achievement in high-risk patients from French general practice","volume":"40","author":"Ferrieres J","year":"2018","unstructured":"Ferrieres J, Gorcyca K, Iorga SR, Ansell D, Steen DL. Lipid-lowering therapy and goal achievement in high-risk patients from French general practice. Clin. Ther. 40(9), 1484\u20131495 e1422 (2018).","journal-title":"Clin. Ther."},{"issue":"2","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcna.2020.10.004","article-title":"Statin-associated myalgias and muscle injury-recognizing and managing both while still lowering the low-density lipoprotein","volume":"105","author":"Mammen AL","year":"2021","unstructured":"Mammen AL. Statin-associated myalgias and muscle injury-recognizing and managing both while still lowering the low-density lipoprotein. Med. Clin. North Am. 105(2), 263\u2013272 (2021).","journal-title":"Med. Clin. North Am."},{"issue":"1","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker BA","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS Effect of statins on skeletal muscle function. Circulation 127(1), 96\u2013103 (2013).","journal-title":"Circulation"},{"issue":"34","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a Meta-Analysis","volume":"43","author":"Byty\u00e7i I","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP Prevalence of statin intolerance: a Meta-Analysis. Eur. Heart J. 43(34), 3213\u20133223 (2022).","journal-title":"Eur. Heart J."},{"issue":"13","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.283.13.1715","article-title":"Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality","volume":"283","author":"Peabody JW","year":"2000","unstructured":"Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 283(13), 1715\u20131722 (2000).","journal-title":"JAMA"},{"key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2288-8-50","article-title":"Vignette studies of medical choice and judgement to study caregivers' medical decision behaviour: systematic review","volume":"8","author":"Bachmann LM","year":"2008","unstructured":"Bachmann LM, Muhleisen A, Bock A, Ter Riet G, Held U, Kessels AG. Vignette studies of medical choice and judgement to study caregivers' medical decision behaviour: systematic review. BMC Med. Res. Methodol. 8, 50 (2008).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T16:13:39Z","timestamp":1702052019000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":35,"alternative-id":["10.57264\/cer-2022-0181"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0181","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"article-number":"e220181"}}